EP1718627A4 - Verfahren zur herstellung von optisch aktivem cetirizin oder dessen salz - Google Patents

Verfahren zur herstellung von optisch aktivem cetirizin oder dessen salz

Info

Publication number
EP1718627A4
EP1718627A4 EP05726293A EP05726293A EP1718627A4 EP 1718627 A4 EP1718627 A4 EP 1718627A4 EP 05726293 A EP05726293 A EP 05726293A EP 05726293 A EP05726293 A EP 05726293A EP 1718627 A4 EP1718627 A4 EP 1718627A4
Authority
EP
European Patent Office
Prior art keywords
formula
optically active
cetirizine
compound
chlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05726293A
Other languages
English (en)
French (fr)
Other versions
EP1718627A1 (de
Inventor
Jae-Shin Kim
Y-K Park
Mun-Choun Ha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanlim Pharmaceutical Co Ltd
Original Assignee
Hanlim Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanlim Pharmaceutical Co Ltd filed Critical Hanlim Pharmaceutical Co Ltd
Publication of EP1718627A1 publication Critical patent/EP1718627A1/de
Publication of EP1718627A4 publication Critical patent/EP1718627A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Definitions

  • the present invention relates to a method for optical resolution of racemic cetirizine or its salt. More particularly, the present invention relates to a process for preparing optically active cetirizine or its salt from racemic cetirizine or its salt using glutamate of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-l-piperazinyl]ethoxy]acetic ester, and the glutamate of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-l-piperazinyl]ethoxy]acetic ester useful as an intermediate for the preparation of the optically active cetirizine or its salt.
  • Background Art
  • Cetirizine is a material known as an antihistamine represented by the following structural formula. Generally, cetirizine is used in its dihydrochloride form and its chemical name is 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-l-piperazinyl]ethoxy]acetic acid.
  • U.K Patent No. 2,225,321 discloses a process for preparing an optical isomer of cetirizine, that is, a process for preparing optically active cetirizine or its salt using optically active ace- tonitrile derivative as an intermediate.
  • U.S. Patent No. 5,478,941 discloses a process for preparing optically active cetirizine or its salt using (4-mefhylphenyl)sulfonyl-piperazine derivative as an intermediate.
  • the present invention provides a process for preparing optically active cetirizine or its salt.
  • the present invention also provides a compound useful as an intermediate for preparation of optically active cetirizine or its salt.
  • a process for preparing optically active cetirizine or its salt including: (a) reacting an optically active compound represented by formula 1 below with a base to prepare an optically active compound represented by formula 2a below; and (b) hydrolyzing the compound of the formula 2a:
  • R 1 is alkyl of C -C and R 2 is an amino protecting group.
  • the amino protecting group may be a common amino protecting group, for example, phenylsulfonyl, unsubstituted or substituted by lower alkyl of C -C ; sulfonyl 1 4 substituted by lower alkyl of C -C ; acetyl; ethoxycarbonyl; t-butoxycarbonyl; benzy- 1 4 loxycarbonyl; benzoyl; nicotinoyl; phthaloyl; or the like.
  • the amino protecting group may be phenylsulfonyl or (4-methylphenyl)sulfonyl.
  • the base that can be used in operation (a) is a common organic or inorganic base.
  • the base include sodium hydrogen carbonate, sodium carbonate, potassium hydrogen carbonate, potassium carbonate, sodium hydroxide, and potassium hydroxide.
  • Operation (a) may be performed in a mixed solvent of a non-polar organic solvent and water, preferably a mixed solvent of methylene chloride and water or a mixed solvent of ethyl acetate and water.
  • the mixture ratio of the non-polar organic solvent to water is about 1 to 1 (v/v).
  • the optically active compound of the formula 2a can be separated using a common method, for example, by extraction of an organic layer followed by washing (if necessary), drying, and concentration.
  • amino protecting group-containing glutamic acids can be reused after recovery. That is, amino protecting group-containing glutamic acids obtained in operation (a) are mobilized to a water layer. The water layer is adjusted to pH 3 or less by addition of hydrochloric acid (HC1) and extracted with an organic solvent such as ethyl acetate. A combined organic layer is dried, filtered, and washed by common methods. An organic phase is concentrated, crystallized in an organic solvent such as diisopropylether, and filtered, to recover the amino protecting group-containing glutamic acids (yield: about 82 %) for reuse.
  • HC1 hydrochloric acid
  • an organic solvent such as ethyl acetate
  • a combined organic layer is dried, filtered, and washed by common methods.
  • An organic phase is concentrated, crystallized in an organic solvent such as diisopropylether, and filtered, to recover the amino protecting group-containing glutamic acids (yield: about 82 %) for reuse.
  • the hydrolysis reaction of operation (b) may be performed in an acidic or basic condition.
  • a basic condition is preferable.
  • Hydrolysis reaction in a basic condition may be performed using 1-2 equivalents of sodium hydroxide or potassium hydroxide.
  • the hydrolysis reaction may be performed in alcohol such as methanol, ethanol, and isopropanol, or a mixed solvent of alcohol and water, preferably in a mixed solvent of methanol and water.
  • the ratio (v/v) of alcohol to water may be about 4 to 6.
  • the hydrolysis reaction may be performed at 0 °C to reflux temperature, preferably 20 to 40 °C .
  • a reaction solution may be purified by washing with ethyl acetate.
  • a washed aqueous solution may be adjusted to pH 4-5 by addition of HC1 and extracted with methylene chloride.
  • Organic phases are combined and dried by a common method.
  • a hydrolysate obtained in operation (b) may react with HC1 in the presence of an organic solvent such as acetone to prepare optically active cetirizine hydrochloride.
  • optically active compound of the formula 1 used as a starting material in the preparation process of the present invention may be prepared by reacting a racemic compound represented by formula 2b below with an optically active compound represented by formula 3 below:
  • the compound of the formula 2b may be easily prepared by a preparation process disclosed in European Patent No. EP 58146 or by esterification of cetirizine dihydrochloride in alcohol in the presence of acid catalyst.
  • the compound of the formula 3 is commercially available or may be prepared by reacting glutamic acid with a common amino protecting group.
  • the amino protecting group may be phenylsulfonyl, unsubstituted or substituted by lower alkyl of C -C ; sulfonyl substituted by lower alkyl of C -C ; acetyl; ethoxycarbonyl; t-butoxycarbonyl; benzyloxycarbonyl; benzoyl; nicotinoyl; phthaloyl; or the like.
  • the amino protecting group may be phenylsulfonyl or (4-methylphenyl)sulfonyl.
  • the compound of the formula 3 may be prepared by reacting glutamic acid with phenylsulfonyl chloride or (4-methylphenyl)sulfonyl chloride in a mixed solvent of a common organic solvent and water, for example a mixed solvent of tetrahydrofuran and water, in the presence of a base such as triethylamine.
  • the reaction between the compound of the formula 2b and the optically active compound of the formula 3 may be performed in alcohol selected from the group consisting of methanol, ethanol, and isopropanol, or a mixed solvent of alcohol and water, preferably in ethanol, isopropanol, or a mixed solvent of isopropanol and water (95:5, v/v).
  • the compound of the formula 3 may react with the compound of the formula 2b in a mole ratio of 0.4-2.2 to 1, preferably 0.4-1.1 to 1.
  • the reaction between the compound of the formula 2b and the optically active compound of the formula 3 may be performed at 0 °C to reflux temperature, preferably at about 60 to 82 °C (or reflux temperature of a solvent).
  • optically active compound of the formula 1 obtained after the reaction between the compound of the formula 2b and the optically active compound of the formula 3 is recrystallized in alcohol selected from the group consisting of methanol, ethanol, and isopropanol, or a mixed solvent of alcohol and water, to obtain a purer product.
  • the re- crystallization may be performed as follows: a solid obtained by gradual cooling after reflux is filtered at 20 to 40 °C , preferably at 25-30 °C , to obtain a purer product.
  • the thus obtained compound of the formula 1 is an optically active compound. Therefore, the compound of the formula 1 can be used for preparation of optically active cetirizine or its salt. That is, an optically pure compound of the formula 1 may be separated using a common filtration process.
  • the compound of the formula 2b reacts with an L-isomer of the compound of the formula 3 to obtain a dextrorotatory compound of the formula 1 which then reacts with a base followed by hydrolysis and reaction with HC1 to obtain levorotatory cetirizine • dihydrochloride. Also, the compound of the formula 2b reacts with a D-isomer of the compound of the formula 3 to obtain a levorotatory compound of the formula 1 which then reacts with a base followed by hydrolysis and reaction with HC1 to obtain dextrorotatory cetirizine • dihydrochloride.
  • optical purity was measured by high-performance liquid chromatography (HPLC) (CHIRALCELL OD-R column, 250 x 4.6 mm, water (0.5 M NaClO , pH 2 buffer)-acetonitrile, 60:40 (v/v) mixed solvent, flow rate 0.5 ml/min) on a chiral stationary phase.
  • HPLC high-performance liquid chromatography
  • polarity was measured using JASCO P-1030
  • nuclear magnetic resonance (NMR) spectrum was measured using 300 MHz FT-NMR Spectrometer (JEOL JNM-LA300), and a melting point was measured using Buchi B- 545.
  • Example 1 preparation of racemic methyl 2-r2-r4-r(4-chloropheny phenylmethyll - 1-piperazinyllethoxyl acetate
  • the resultant solution was adjusted to pH 3 or less by addition of 33.3 ml (0.2 mole) of a 6 N hydrochloric acid solution and extracted with 150 ml of ethyl acetate continuously three times.
  • a combined organic phase was washed with 100 ml of an aqueous saturated sodium chloride solution.
  • the washed organic phase was dried over anhydrous magnesium sulfate, filtered, washed with ethyl acetate, and concentrated.
  • the concentrate was crystallized by addition of 150 ml of diisopropylether.
  • the resultant solid was filtered and washed with a small quantity of diisopropylether to give 21.79 g of (+)-N-(phenylsulfonyl)-D-glutamic acid as a desired product.
  • Example 3 preparation of (-VN-r(4-methylphenyl)sulfonyll -D-glutamic acid
  • Example 4 preparation of dextrorotatory methyl 2- [2- [4- [(4-chlorophenyl)phenylmethyll - 1 -piperazinyll ethoxyl acetate • N- (phenylsulfonyl)-L- glutamate
  • the reaction solution was cooled to room temperature, and the precipitated solid was filtered, washed with a small quantity of a mixed solvent of isopropanol and water, and dried.
  • the dried solid was recrystallized in a mixed solvent (95:5, v/v) of isopropanol and water to give 7.68 g of dextrorotatory methyl 2- [2- [4- [(4-chlorophenyl)phenylmethyl] - 1 -piperazinyl] ethoxy ] acetate • N- (phenylsulfonyl)-L-glutamate.
  • Example 5 preparation of levorotatory methyl 2- [2- [4- [(4-chlorophenyl)phenylmethyll - 1 -piperazinyll ethoxyl acetate • N- (phenylsulfonylVD- lutamate [65] 15.19 g (0.038 mole) of the racemic methyl 2-[2-[4-[(4-chlorophenyl)phenylmethyl ]-l-piperazinyl]efhoxy]acetate prepared in Example 1 was dissolved in 150 ml of a mixed solvent (95:5, v/v) of isopropanol and water, heated to 60 °C , and then stirred for one hour after addition of 11.00 g (0.038 mole) of (+)-N- (phenylsulfonyl) -D-glutamic acid prepared in Example 2.
  • reaction solution was cooled to room temperature, and the precipitated solid was filtered, washed with a small quantity of a mixed solvent of isopropanol and water, and dried.
  • the dried solid was recrystallized in a mixed solvent (95:5, v/v) of isopropanol and water to give 8.47 g of levorotatory methyl 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-l-piperazinyl]ethoxy ] acetate • N-(phenylsulfonyl)-D-glutamate.
  • Example 6 preparation of dextrorotatory methyl 2- [2- [4- [(4-chlorophenyl)phenylmethyll - 1 -piperazinyll ethoxyl acetate • N- [(4-methylphenyl)sulfonyll-L-glutamate
  • Example 7 preparation of dextrorotatory methyl 2- [2- [4- [(4-chlorophenyl)phenylmethyll - 1 -piperazinyll ethoxyl acetate • N- r(4-methylphenyl)sulfonyll-L-glutamate
  • Example 8 preparation of levorotatory methyl 2- [2- [4- [(4-chlorophenyl)phenylmethyll - 1 -piperazinyll ethoxyl acetate • N- [(4-methylphenyl)sulfonyll -D-glutamate
  • the reaction solution was cooled to room temperature, and the precipitated solid was filtered, washed with a small quantity of a mixed solvent of isopropanol and water, and dried.
  • the dried solid was recrystallized in a mixed solvent (95:5, v/v) of isopropanol and water to give 10.10 g of levorotatory methyl 2-[2-[4-[(4-chlorophenyl)phenylmethyl] - 1 -piperazinyl] ethoxy ] acetate • N- [(4-methylphenyl)sulfonyl] -D-glutamate.
  • Example 10 preparation of levorotatory 2-r2-r4-r(4-chloropheny phenylmethyll - 1-piperazinyllethoxyl acetic acid • dihydrochloride (cetirizine • dihydrochloride)
  • Example 11 preparation of levorotatory 2-r2-r4-r(4-chloropheny phenylmethyll - 1-piperazinyllethoxyl acetic acid • dihydrochloride (cetirizine • dihydrochloride [ 104] 1.84 g of levorotatory 2- [2- [4- [(4-chlorophenyl)phenylmethyl] - 1 -piperazinyl] ethoxy] acetic acid • dihydrochloride was prepared in the same manner as in Example 10 using 3.25 g (4.62 mmole) of the dextrorotatory methyl 2- [2- [4- [(4-chlorophenyl)phenylmethyl] - 1 -piperazinyl] ethoxy] acetate • N- [(4-methylphenyl)sulfonyl]-L-glutamate prepared in Example 7.
  • Example 12 preparation of dextrorotatory 2-[2-[4-[(4-chlorophenyl)phenylmethyll -1 -piperazinyll ethoxyl acetic acid • dihydrochloride (cetirizine • dihydrochloride)
  • the concentrate was dissolved in 9.1 ml of methanol and 13.6 ml of a IN aqueous sodium hydroxide solution was gradually added thereto.
  • the reaction mixture was stirred at room temperature for 3 hours and then washed with 91 ml of ethyl acetate after addition of 77.4 ml of water.
  • the aqueous solution phase was adjusted to pH 4-5 by addition of a IN hydrochloric acid solution and extracted with 91 ml of methylene chloride continuously three times.
  • a combined organic phase was dried over anhydrous magnesium sulfate, filtered, washed with methylene chloride, and concentrated.
  • Example 13 preparation of dextrorotatory 2-r2-r4-r(4-chlorophenyl)phenylmethyll -1 -piperazinyll ethoxyl acetic acid • dihydrochloride (cetirizine • dihydrochloride)
  • Example 12 After 91 ml of ethyl acetate was added to 9.10 g (0.013 mole) of the levorotatory methyl 2- [2- [4- [(4-chlorophenyl)phenylmethyl] - 1 -piperazinyl] ethoxy] acetate • N-[(4-methylphenyl)sulfonyl]-D-glutamate prepared in Example 8, 91 ml of a 0.5 M aqueous sodium hydrogen carbonate solution was gradually added and stirred for one hour, and then an organic phase was extracted, a residual aqueous solution of 0.5 M sodium hydrogen carbonate was adjusted to pH 3 or less by addition of 47 ml of IN hydrochloric acid solution and extracted with 50 ml of ethyl acetate continuously three times.
  • optical resolution of racemic cetirizine or its salt using glutamate of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-l-piperazinyl]ethoxy] acetic ester can produce optically active cetirizine or its salt with high yield and purity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP05726293A 2004-02-02 2005-01-27 Verfahren zur herstellung von optisch aktivem cetirizin oder dessen salz Withdrawn EP1718627A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020040006608A KR100503443B1 (ko) 2004-02-02 2004-02-02 광학적으로 활성인 세티리진 또는 그의 염의 제조방법
PCT/KR2005/000231 WO2005073207A1 (en) 2004-02-02 2005-01-27 Process for preparing optically active cetirizine or its salt

Publications (2)

Publication Number Publication Date
EP1718627A1 EP1718627A1 (de) 2006-11-08
EP1718627A4 true EP1718627A4 (de) 2007-04-18

Family

ID=34825062

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05726293A Withdrawn EP1718627A4 (de) 2004-02-02 2005-01-27 Verfahren zur herstellung von optisch aktivem cetirizin oder dessen salz

Country Status (3)

Country Link
EP (1) EP1718627A4 (de)
KR (1) KR100503443B1 (de)
WO (1) WO2005073207A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1858866T3 (pl) * 2005-03-03 2009-11-30 Ucb Farchim Sa Sole piroglutaminiany i ich zastosowanie do rozdzielania optycznego związków pośrednich do syntezy dekstrocetyryzyny i lewocetyryzyny
KR100954755B1 (ko) * 2007-12-17 2010-04-27 한미약품 주식회사 (ｒ)-(-)-1-[(4-클로로페닐)페닐메틸]피페라진의 제조방법
KR100998067B1 (ko) 2008-09-08 2010-12-03 주식회사 삼오제약 비스(1-[(4-클로로페닐)페닐메틸]피페라진)-2,3-디벤조일 타르타르산 신규 중간체 염 및 이를 이용한 광학 활성적으로 순수한 1-[(4-클로로페닐)페닐메틸]피페라진을 분리하는 분리방법
KR102491445B1 (ko) * 2021-01-05 2023-01-25 (주)분자와물질 광학분할에 의한 새로운 레보세티리진의 제조방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0058146A1 (de) * 1981-02-06 1982-08-18 U C B, S.A. 2-(4-(Diphenylmethyl)-1-piperazinyl)-essigsäure und ihre Amide, Verfahren zu ihrer Bereitung und pharmazeutische Zusammensetzungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827391D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
GB9305282D0 (en) 1993-03-15 1993-05-05 Ucb Sa Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine
BE1010094A3 (fr) * 1996-04-10 1997-12-02 Ucb Sa Nouveaux [2-(1-piperazinyl)ethoxy] methyle substitues.
IL124195A (en) * 1998-04-23 2000-08-31 Chemagis Ltd Process for the preparation of esters of 2-¬4-¬4-chlorophenyl¾phenylmethyl¾-1-piperazinyl¬ethoxy¾acetic acid
IT1314184B1 (it) * 1999-08-12 2002-12-06 Nicox Sa Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
US6265579B1 (en) * 1999-10-29 2001-07-24 Salsbury Chemicals, Inc. Process for preparing piperazine-substituted aliphatic carboxylates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0058146A1 (de) * 1981-02-06 1982-08-18 U C B, S.A. 2-(4-(Diphenylmethyl)-1-piperazinyl)-essigsäure und ihre Amide, Verfahren zu ihrer Bereitung und pharmazeutische Zusammensetzungen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PFLUM, D. A. ET AL: "A Large-Scale Synthesis of Enantiomerically Pure Cetirizine Dihydrochloride Using Preparative Chiral HPLC", ORGANIC PROCESS RESEARCH & DEVELOPMENT , 5(2), 110-115 CODEN: OPRDFK; ISSN: 1083-6160, March 2001 (2001-03-01), XP002255197 *
See also references of WO2005073207A1 *

Also Published As

Publication number Publication date
EP1718627A1 (de) 2006-11-08
WO2005073207A1 (en) 2005-08-11
KR100503443B1 (ko) 2005-07-22

Similar Documents

Publication Publication Date Title
US20040242875A1 (en) Novel processes
US11897843B2 (en) Process for the preparation of enantiomerically enriched 3-aminopiperidine
JP6568221B2 (ja) ベンゾオキサゾールオキサジンケトン系化合物の製造方法及びその中間体と結晶形
CA2961984C (en) Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines
WO2005073207A1 (en) Process for preparing optically active cetirizine or its salt
TWI491607B (zh) ４，４’-（１-甲基-１，２-乙二基）-雙-（２，６-哌二酮）之新製法
JP2010111684A (ja) キラル２−メチル−４−保護化ピペラジンの立体選択的アルキル化
EP2062881B1 (de) Verfahren zur Herstellung von N-(Diphenylmethyl)piperazinen
US7989623B2 (en) Process for making n-(diphenylmethyl)piperazines
RU2248974C2 (ru) Способ получения {2-[4-(альфа-фенил-п-хлорбензил)пиперазин-1-ил]-этокси}-уксусной кислоты и новые промежуточные соединения
US20060183903A1 (en) Piperazine derivatives and their use as synthesis intermediates
US5252747A (en) Chiral quinolone intermediates
KR100928776B1 (ko) (ｒ)-1-[(4-클로로페닐)페닐메틸]피페라진 또는 이의 염의제조방법
JP2001097933A (ja) 光学活性２−アミノシクロヘキサノール誘導体の製造法
JP4524841B2 (ja) 光学活性アミノ酸エステル酒石酸アミドおよびその製造法
WO2009078627A2 (en) Method for preparing (r)-(-)-1-[(4-chlorophenyl)phenylmethyl]piperazine
US5710321A (en) Process for preparing the cyclohexylamine salt of (+) - threo-2-hydroxy-3-(2'-aminophenylthio) -3-(4"-methoxyphenyl) -propionic acid and of its (-) -antipode"
US8383833B2 (en) Method for producing optically active amino acid derivative
CN115594613A (zh) 依度沙班中间体及其制备方法
JP3656002B2 (ja) 光学活性アミドカルボン酸の製造方法および精製方法
CN117015542A (zh) 吡咯并吡啶衍生物的制备方法
JP2002179634A (ja) Ｎ−メチレングリシネートの製法
JP2001278865A (ja) ４−アミノキノリン類の製造方法
HU226641B1 (en) Process for producing {2-[4-(alpha-phenyl-p-chloro-benzyl)-piperazine-1-yl]-ethoxy}-acetic acid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060901

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20070320

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20110519

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120801